Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2014 April;66(2) > Minerva Ginecologica 2014 April;66(2):179-92

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GINECOLOGICA

A Journal on Obstetrics and Gynecology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

  TARGETING OVARY DISORDERS


Minerva Ginecologica 2014 April;66(2):179-92

language: English

New paradigms in the surgical and adjuvant treatment of ovarian cancer

Hodeib M., Eskander R. N., Bristow R. E.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of California, Irvine, Orange, CA, USA


PDF  


Advanced stage epithelial ovarian cancer is difficult to treat. Despite advances in surgical resection and adjuvant chemotherapy the majority of patients suffer from disease recurrence. In an effort to improve oncologic outcomes, including progression free and overall survival, novel surgical paradigms and chemotherapeutic techniques have emerged over the past decade. An emphasis has been placed on achieving maximal surgical cytoreduction (defined as no visible residual disease) at completion of surgery, in combination with intra-peritoneal (IP) chemotherapy, as well as hyperthermic IP chemotherapy (HIPEC). This review article will discuss the evolution of surgical cytoreduction in the treatment of advanced stage epithelial ovarian cancer, as well as the development of adjuvant treatments that increasingly utilize the biologic advantage provided by microscopic residual disease.

top of page

Publication History

Cite this article as

Corresponding author e-mail

Eskander@uci.edu